Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Non-Current Liabilities (2017 - 2025)

Crinetics Pharmaceuticals has reported Total Non-Current Liabilities over the past 5 years, most recently at $130.9 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $130.9 million for Q4 2025, up 20.17% from a year ago — trailing twelve months through Dec 2025 was $130.9 million (up 20.17% YoY), and the annual figure for FY2025 was $130.9 million, up 20.17%.
  • Total Non-Current Liabilities for Q4 2025 was $130.9 million at Crinetics Pharmaceuticals, up from $121.0 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for CRNX hit a ceiling of $130.9 million in Q4 2025 and a floor of $96.2 million in Q4 2023.
  • Median Total Non-Current Liabilities over the past 3 years was $107.3 million (2024), compared with a mean of $110.9 million.
  • Peak annual rise in Total Non-Current Liabilities hit 20.17% in 2025, while the deepest fall reached 10.66% in 2025.
  • Crinetics Pharmaceuticals' Total Non-Current Liabilities stood at $96.2 million in 2023, then grew by 13.21% to $109.0 million in 2024, then grew by 20.17% to $130.9 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $130.9 million (Q4 2025), $121.0 million (Q3 2025), and $115.7 million (Q2 2025) per Business Quant data.